Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver ...

Eisai and Biogen have announced that the US FDA has accepted for review the sBLA submitted by the former for Leqembi Iqlik SC ...

A new report has revealed that 83% of life sciences CEOs view Internet of Medical Things (IoMT) devices as the most important ...

The lack of initial public offerings (IPOs) also reflects a year of restricted growth. As per the BIA, no UK biotechs went ...

The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.

The UK's NICE now recommends the NHS use of Pfizer's daily prostate cancer pill, Talzenna alongside hormone therapy Xtandi.

The key element of the agreement is confirmation that UK pharmaceutical exports to the US will face a preferential tariff ...

Staying ahead of pharma supply challenges rests on anticipatory pillars and does not require reinventing the wheel, says ...

AstraZeneca has agreed to buy AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

GSK's RAPT Therapeutics acquisition will strengthen the former's immunology pipeline – specifically its offerings for food ...

Bristol Myers Squibb (BMS) has entered into an agreement with Microsoft to advance AI-driven early lung cancer detection.

As more drugs go subcutaneous, CEO of Phillips Medisize, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.